2018 Virtual Symposium: Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

Activity Title: 2018 Virtual Symposium: Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

Activity Format: Virtual Symposium

Program Description:
Kidney disease has been recognized as a complication of type 2 diabetes mellitus (T2DM) since the 1950s, developing in approximately 35% of patients with T2DM and affecting as many as 50% of patients with diabetes through a 20 years' duration. The prevalence of diabetic kidney disease (DKD) in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among adults with diabetes, the prevalence of DKD has remained stable despite increased use of antihyperglycemic agents and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Newer glucose-lowering agents appear to have glucose-independent effects on diabetic nephropathy and its progression. Recently published data from clinical trials assessing cardiovascular outcomes of SGLT2 inhibitors and GLP-1 receptor agonists (RAs) show positive affects on the development and progression of DKD.

This virtual symposium will utilize interactive infographics to provide an overview of the renal effects of antiglycemic agents, particularly GLP-1 RAs and SGLT2 inhibitors. Experts will identify patients who are at the greatest risk for DKD, discuss the underlying physiology of DKD, provide an overview of the mechanisms of action of SGLT2 inhibitors and GLP-1 RAs in relation to renal physiology, and how to effectively manage patients with T2DM and DKD based on the benefits and risks of SGLT2 inhibitors and GLP-1 RAs.

Estimated Time to Complete: 1.0 hour

Release Date: December 24, 2018

Expiration Date: December 24, 2019

Credit Type(s) Available: ACCME, ANCC, ACPE, CDR

Maximum Credits: 1.0

Joint Providership Statement: This activity is jointly provided by The University of Cincinnati and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ACCME credit. This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ANCC, CDR and ACPE credit.

Educational Grant Support:
This activity is supported by educational grants from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. and by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Target Audience:
The educational design of this activity addresses the needs of US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Educational Objectives:
After completing this activity, the participant should be better able to:

• Describe the relationship between T2DM, hypertension, and cardiorenal syndrome
• Review the most current T2DM algorithms and guidelines for the individualized treatment of complex patients, specifically those with DKD
• Summarize the mode of action and effects of GLP-1 RAs and SGLT-2 inhibitors on renal physiology in patients with T2DM and DKD
• Develop management plans for T2DM patients that consider the recently discovered renal effects of SGLT2 inhibitors and GLP-1 RAs

Faculty Information:

Disclosure of Conflicts of Interest:

The University of Cincinnati requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the University of Cincinnati for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditor Disclosures:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams; Bruce Gebhardt, MD; Susan P. Tyler, M.Ed., CMP, CHCP, FACEHP all have nothing to disclose.

Accreditation:

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CMHC.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement(s):

Physician Credit Designation
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.00 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This activity includes 0.9 pharmacotherapy hours.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 1.00 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Number (UAN): 0530-9999-18-426-H01-P

Dietician Accreditation Statement
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials.

CPE Provider #GE012

University of Cincinnati Contact Information:

For information about the accreditation of this program, please contact UC at 513-558-7277 or uc-cloudcme@ucmail.uc.edu

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Cincinnati and CMHC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for CME/CE Credit:

This activity is offered at no cost to participants. During the period December 24, 2018 through December 24, 2019, participants must follow these steps in order to receive CME/CE credit:

• Sign In or Register at https://www.cardiometabolichealth.org/my-account.html
• Read and accept the Terms & Conditions including the learning objectives and faculty disclosures.
• Complete the pre-test by recording the best answer to each question in the answer key. There is no scoring of the pre-test questions section.
• Review the educational activity.
• Complete the post-test by recording the best answer to each question in the answer key. Successful completion of the post-test is required to earn CME/CE credit. Successful completion is defined as a cumulative score of at least 70%.
• Complete the online evaluation form.
• After successfully completing the post-test and online evaluation form, your CME/CE certificate will be generated and will be available immediately for print.

Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6-10 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed.

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements:

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.